Frequency of kidney disease in chronic sarcoidosis.
…, M Hoffmann, R Waldherr, M Uppenkamp - … , vasculitis, and diffuse …, 2003 - europepmc.org
Sarcoidosis is an immunemediated disease of unknown cause, characterized by noncaseating
epithelioid granulomas, affecting multiple organs. Clinically apparent renal involvement …
epithelioid granulomas, affecting multiple organs. Clinically apparent renal involvement …
Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides
…, H Sattler, L Peters, U Löffler, M Uppenkamp… - The Journal of …, 2015 - jrheum.org
Objective. Differentiating gout, calcium pyrophosphate deposition disease (CPPD), and non–crystal-related
inflammatory arthropathies (non-CRA) is essential but often clinically …
inflammatory arthropathies (non-CRA) is essential but often clinically …
Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations
…, DW Beelen, M Uppenkamp… - British journal of …, 2011 - Wiley Online Library
In AML, cooperation of mutations suppressing differentiation (‘class‐II‐mutations’) with ‘class‐I‐mutations’
increasing cell proliferation is frequent. In rare cases of myeloid malignancies, …
increasing cell proliferation is frequent. In rare cases of myeloid malignancies, …
Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET
…, M Hoffmann, R Bergner, M Uppenkamp… - Clinical nuclear …, 2009 - journals.lww.com
Methods: Dynamic positron emission tomography (PET) studies with F-18-deoxyglucose
were performed in patients with multiple myeloma who received anthracycline-based …
were performed in patients with multiple myeloma who received anthracycline-based …
Rearranged antigen receptor genes in Hodgkin's disease [published erratum appears in Blood 1987 Sep; 70 (3): 893]
J Sundeen, E Lipford, M Uppenkamp, E Sussman… - 1987 - ashpublications.org
Despite intensive efforts using a wide variety of approaches, the cellular lineage and clonality
of the abnormal cells of Hodgkin's disease have remained an enigma. In the present study, …
of the abnormal cells of Hodgkin's disease have remained an enigma. In the present study, …
[HTML][HTML] Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia—a phase 3 study
…, WD Ludwig, H Biersack, YD Ko, MJ Uppenkamp… - Leukemia, 2018 - nature.com
Dose-dense induction with the S-HAM regimen was compared to standard double induction
therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were …
therapy in adult patients with newly diagnosed acute myeloid leukemia. Patients were …
Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg
…, DM Henrich, WE Haefeli, M Uppenkamp… - Nephrology Dialysis …, 2006 - academic.oup.com
To cover intermediate sensitive Candida glabrata in ICU patients, fluconazole plasma peak
levels at least in the range of 16–32 µg/ml appear necessary for treatment. Previous studies …
levels at least in the range of 16–32 µg/ml appear necessary for treatment. Previous studies …
Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease
…, D Henrich, M Hoffmann, M Uppenkamp - Oncology Research …, 2006 - karger.com
Renal dysfunction is a particularly problematic adverse event that requires additional
management and can prohibit the use of certain medications. Due to their renal uptake and …
management and can prohibit the use of certain medications. Due to their renal uptake and …
Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study
…, K Dill, D Boerner, M Uppenkamp - Nephrology Dialysis …, 2002 - academic.oup.com
Background. Ibandronate is an inhibitor of osteoclast‐mediated bone resorption. This
therapeutic effect is utilized in the treatment of osteoporosis and metastatic bone disease. The …
therapeutic effect is utilized in the treatment of osteoporosis and metastatic bone disease. The …
CD34+ Cell Enrichment for Autologous Peripheral Blood Stem Cell Transplantation by Use of the CliniMACS Device
Després, T Flohr, M Uppenkamp, M Baldus… - … of hematotherapy & …, 2000 - liebertpub.com
Several devices for selection of CD34 + peripheral blood stem cells (PBSC) have been used
during the last years for reducing tumor cell contamination of the graft. The new CliniMACS …
during the last years for reducing tumor cell contamination of the graft. The new CliniMACS …